Renal carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Disease-free survival curves of Kif11 with different cancers and the relationships between Kif11 and the von Hippel-Lindau disease tumour suppressor gene (<i>VHL</i>), and proliferating cell nuclear antigen (PCNA) in kidney cancer were further analysed using the GEPIA database.
|
30819726 |
2019 |
Renal carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Glycolysis and antioxidant pathways in kidney cancer are elevated, with frequent mutation of the VHL gene.
|
28408240 |
2017 |
Renal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inactivation of the von Hippel-Lindau tumor suppressor protein (pVHL) is the signature lesion in the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC). pVHL loss causes the transcriptional activation of hypoxia-inducible factor (HIF) target genes, including many genes that encode histone lysine demethylases.
|
28701475 |
2017 |
Renal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, complex indels display strong tissue specificity (such as VHL in kidney cancer samples and GATA3 in breast cancer samples).
|
26657142 |
2016 |
Renal carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We also show that analysis of mutations in VHL using our workflow provides valuable insights into the effects of mutations, and their links to the risk of developing renal carcinoma.
|
26797105 |
2016 |
Renal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
VHL-deficient clear cell renal cell carcinomas (ccRCC), the most common form of kidney cancer, express transcripts derived from the novel human endogenous retrovirus HERV-E (named CT-RCC HERV-E).
|
26862115 |
2016 |
Renal carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Clear cell renal cell carcinoma (ccRCC) is the major subtype of kidney cancer that is characterized by frequent inactivation of the von Hippel-Lindau (VHL) gene in 80-90% of the tumors.
|
25873528 |
2015 |
Renal carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
It exhibits a different molecular signature than clear-cell carcinoma and is typically not associated with mutations in the VHL (von Hippel-Lindau) tumor suppressor gene. pRCC is less responsive to modern drugs introduced in the management of kidney cancer in the past decade.
|
24629521 |
2014 |
Renal carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Somatic mutations or loss of expression of tumor suppressor VHL happen in the vast majority of clear cell Renal Cell Carcinoma, and it's causal for kidney cancer development.
|
24260413 |
2013 |
Renal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.
|
23223005 |
2013 |
Renal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Renal cancer is resistant to conventional chemotherapy and radiotherapy but increased understanding of the underlying tumour biology is leading to the use and development of targeted therapies, such as tyrosine kinase inhibitors targeting pathways downstream of the von Hippel Lindau tumour suppressor gene.
|
23228867 |
2013 |
Renal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
While seven FDA-approved agents that target the VHL pathway have been approved for the treatment of patients with advanced kidney cancer, further genomic studies, such as whole genome sequencing, gene expression patterns, and gene copy number, will be required to gain a complete understanding of the genetic basis of kidney cancer and of the kidney cancer gene pathways and, most importantly, to provide the foundation for the development of effective forms of therapy for patients with this disease.
|
23038766 |
2012 |
Renal carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer.
|
21602888 |
2011 |
Renal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review aims to focus on pathways in renal cancer (VHL/HIF, mTOR, c-MYC, c-MET, and immune response) in the respective tumor subtypes, accounting for the effects of targeted therapies and providing the framework to search for relevant predictive biomarkers and propose new trials.
|
21677472 |
2011 |
Renal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
VHL is the gene for clear cell kidney cancer.
|
20059341 |
2010 |
Renal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inactivation of the von Hippel-Lindau tumor suppressor protein (pVHL) causes the most common form of kidney cancer. pVHL is part of a complex that polyubiquitinates the alpha subunit of the heterodimeric transcription factor HIF.
|
20973793 |
2010 |
Renal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The VHL gene is the gene for the hereditary cancer syndrome, von Hippel-Lindau, as well as for the common form of sporadic, noninherited, clear cell kidney cancer.
|
19402075 |
2009 |
Renal carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Loss of VHL function causes the overexpression of transforming growth factor (TGF)-alpha, leading us to hypothesize that TGF-alpha could be a potential TAA for immunotherapy of kidney cancer, which was evaluated in this study.
|
19052740 |
2009 |
Renal carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Clear-cell renal cell carcinoma (RCC) is the most prevalent form of kidney cancer and is frequently associated with loss of von Hippel-Lindau (VHL) gene function, resulting in the aberrant transcriptional activation of genes that contribute to tumor growth and metastasis, including transforming growth factor-alpha (TGF-alpha), a ligand of the epidermal growth factor receptor (EGFR) tyrosine kinase.
|
18243508 |
2008 |
Renal carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Novel somatic mutations of the VHL gene in an erythropoietin-producing renal carcinoma associated with secondary polycythemia and elevated circulating endothelial progenitor cells.
|
17696210 |
2008 |
Renal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Most of what is known about the genetic basis of kidney cancer has been learned from study of the inherited forms of kidney cancer: von Hippel Lindau (VHL gene), hereditary papillary renal carcinoma (c-Met gene), Birt Hogg Dubé (BHD gene), and hereditary leiomyomatosis renal cell cancer (fumarate hydratase gene).
|
17255292 |
2007 |
Renal carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The von Hippel-Lindau tumor suppressor protein (pVHL) is frequently mutated in kidney cancer and is part of the ubiquitin ligase complex that targets prolyl hydroxylated HIFalpha for destruction.
|
17220275 |
2007 |
Renal carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Clear cell renal cell carcinoma (CCRCC) is the most common renal carcinoma and it is often associated with von Hippel-Lindau disease (VHL) gene mutations.
|
16627979 |
2006 |
Renal carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.
|
16488999 |
2006 |
Renal carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The von Hippel-Lindau (VHL) gene is the major renal cancer gene in adults.
|
14973063 |
2004 |